

Carbiotix completes phase one of CarbiAXOS production upgrade in Bjuv

Carbiotix (publ) ("Carbiotix" or the "Company") announces today that the Company has completed phase one of the CarbiAXOS production upgrade at the Company's production site in Bjuv, Sweden. The upgrade involved the commissioning of a production tank and filtration system to produce Carbiotix' second generation CarbiAXOS prebiotic ingredient. The Company anticipates that phase two of the production upgrade will be completed in early Q1 2024, allowing the Company to have full control of its production process and accelerate development activities.

Carbiotix announces today the successful completion of phase one of the production upgrade at the Company's production site in Bjuv, Sweden. The recent upgrade marks a significant advancement in the CarbiAXOS production capabilities and is a key component in Carbiotix's strategic plan to accelerate the creation of high-end CarbiAXOS products.

The second phase of the production upgrade is on track for completion in Q1 2024. This phase is critical as it includes the commissioning of a new spray dryer, which will enable Carbiotix to independently produce CarbiAXOS at our Bjuv site. This self-sufficiency in production will allow the Company to provide samples for formulation testing, as well as produce CarbiAXOS for studies and cosmetic applications.

Erik Deaner, CEO of Carbiotix comments:

"This upgrade is a testament to our commitment to align with the Company's strategic direction. The completion of phase one is not just a milestone but a leap forward for Carbiotix, setting the stage for an exciting future. The independence in production will also allow us to expedite our development activities for new CarbiAXOS products. This means we can more rapidly validate the innovations coming from our R&D lab in Lund. I would like to thank our engineering partners for helping us complete phase one of the process upgrade and look forward to expediting phase two of the upgrade with an expected completion date in early Q1 2024."

Forward-looking statements

This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios as described in this press release.

For further information:

Carbiotix AB
Erik Deaner, CEO
Tel: +46 (0)738 67 30 85
E-mail: erik.deaner@carbiotix.com

Carbiotix AB (CRBX) (www.carbiotix.com) is an award-winning biotechnology company pioneering microbiome healthcare through a portfolio of prebiotic modulators and diagnostic testing services.